Adial Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$57.8MTTM through 30 Jun 2026
Free Cash Flow -$11.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-151.2%ROE
-119.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.42x
Net Debt-$5.9Mnet cash position
Cash & Equivalents$5.9M
Quality Metrics
Altman Z-Score-12.38
Piotroski F-Score3 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$17.71TTMFY2025: $-11.93
Dividend
No dividend
Capital Allocation
R&D Spend$2M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Drug Development | $0 | 0.0% | View detailsThe company is focused on advancing AD04 into a pivotal Phase 3 clinical trial following alignment with the FDA on an adaptive trial design. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.